Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
about
Progress and problems in understanding and managing primary Epstein-Barr virus infectionsViruses and human cancerProgress, prospects, and problems in Epstein-Barr virus vaccine development.Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayAdvances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesKinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.Latent antigen vaccination in a model gammaherpesvirus infection.Structure of the Epstein-Barr virus major envelope glycoprotein.Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays.Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).Is vaccine therapy the future in cancer prevention?
P2860
Q24597706-37EA30D2-7259-4B75-B212-780794BCDE60Q27481175-147914AF-5F9E-475D-8C6E-2F4A76C262F6Q33812640-C3221435-047E-44F6-8F07-9A9C9D2257A8Q34009363-3F145996-E344-44BA-A8EA-4A9DC8F7BFC6Q34597080-D55354CE-8170-4D8F-98AC-366ACAA0D604Q34609654-11ED2496-DC67-456C-B148-FCBC1D4B3E12Q35829978-078F4A41-B821-4C49-B0C8-830A239E8B0BQ36764365-E5B2A50A-1C87-4341-8E0A-37CCD7D87A77Q36979271-769BB323-9DFB-4BE9-A792-8FF6C3661527Q37888687-9A3BABEC-F0A1-4294-A3C3-9C8286FF1690Q39170011-A3B248BB-5E33-4959-88F8-FCAB09F835EAQ39606886-75AC6A7B-0660-40DE-A640-BB0A5709186FQ40214421-EF2051F5-CDDE-46F7-B2FF-25031DCF0F1FQ40967391-44CEEC9D-B64F-414B-B24E-B1789FDD9E8FQ41557807-A1161B6E-5D79-4AA2-B086-97F74B52B3F2Q44817327-776E78AD-A93C-4E82-B996-D8D4032CC3F6Q45399777-72515AA3-90E7-4326-B7EB-D5C334795CBBQ56959463-B636740D-A5B1-4B1F-AB0E-FD118D5F8B33
P2860
Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@en
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@nl
type
label
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@en
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@nl
prefLabel
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@en
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@nl
P2093
P1433
P1476
Expression of Epstein-Barr vir ...... in for an EBV subunit vaccine.
@en
P2093
P304
P356
10.1016/S0264-410X(98)00248-5
P407
P577
1999-02-01T00:00:00Z